{{Rsnum
|rsid=6220
|Gene=IGF1
|Chromosome=12
|position=102400737
|Orientation=plus
|GMAF=0.3526
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=IGF1
}}{{PMID|17911177}} Implications for [[prostate cancer]] of [[IGF1]] the TCC haplotype and the rs6220 SNP were associated with elevated levels of circulating IGF1 (p = 0.001 and <0.0001, respectively)

{{omim
|desc=INSULIN-LIKE GROWTH FACTOR I; IGF1
|id=147440
|rsnum=6220
}}
{{PMID Auto
|PMID=19784788
|Title=Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk
}}

{{PMID Auto
|PMID=21552154
|Title=Common genetic variation in the IGF1 associates with maximal force output
}}

{{PMID|18064566}} Common genetic variation in the IGF-1 gene, serum IGF-I levels and breast density.

{{PMID|18199734|OA=1
}} IGF-I and IGF-II genetic variation and breast cancer risk in Chinese women: results from the Shanghai Breast Cancer Study.

{{PMID|18398029}} Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels.

{{PMID|18562769|OA=1
}} Genetic variation in insulin-like growth factors and brain tumor risk.

{{PMID|18772892|OA=1
}} Can genes for mammographic density inform cancer aetiology?

{{PMID|20302654|OA=1
}} Genotypes and haplotypes in the insulin-like growth factors, their receptors and binding proteins in relation to plasma metabolic levels and mammographic density.

{{PMID|21113804}} IGF1 htSNPs in relation to IGF-1 levels in young women from high-risk breast cancer families: implications for early-onset breast cancer.

{{PMID|21791631|OA=1
}} Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

{{PMID Auto
|PMID=23180020
|Title=Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer
}}

{{PMID Auto
|PMID=23530598
|Title=Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis
|OA=1
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}